Ambu A/S
OTC:AMBFF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (55.1), the stock would be worth $33.54 (146% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.4 | $13.65 |
0%
|
| 3-Year Average | 55.1 | $33.54 |
+146%
|
| 5-Year Average | 114.6 | $69.79 |
+411%
|
| Industry Average | 15.5 | $9.42 |
-31%
|
| Country Average | 13.6 | $8.28 |
-39%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$18B
|
/ |
Jan 2026
kr705m
|
= |
|
|
$18B
|
/ |
Sep 2026
kr847m
|
= |
|
|
$18B
|
/ |
Sep 2027
kr1.1B
|
= |
|
|
$18B
|
/ |
Sep 2028
kr1.5B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DK |
|
Ambu A/S
OTC:AMBFF
|
16.3B USD | 22.4 | 29.8 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 19.1 | 25.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 56.5 | 60.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 24.2 | 39.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 26.4 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 15.6 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 26.1 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 34.1 | 43.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 16.9 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 13.6 | 15.6 |
Market Distribution
| Min | 0.8 |
| 30th Percentile | 6.6 |
| Median | 13.6 |
| 70th Percentile | 19.5 |
| Max | 473.6 |
Other Multiples
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.